Introducing Ivan Kairatov, a renowned Biopharma expert with an extensive background in technology, innovation, and research and development within the pharma industry. Ivan is here to discuss the recent European Commission approval of Tevimbra for nasopharyngeal cancer, a significant milestone in
In today's fast-evolving landscape, artificial intelligence (AI) is reshaping a plethora of industries, notably the realm of clinical trials. AI promises enhanced efficiency, reduced costs, and improved outcomes for medical research. The integration of AI in medical research is stirring interest
Amid rising prevalence and societal impact, addressing Alzheimer's disease demands breakthroughs in research and treatment. The pioneering initiative by the Indiana University School of Medicine, through the TREAT-AD (Target Enablement to Accelerate Therapy Development for Alzheimer's Disease) drug
With a wealth of experience in biopharma and a keen eye for technological advancement, Ivan Kairatov stands at the forefront of innovation in the industry. Today, he shares his insights on the FDA's recent decision to publish complete response letters (CRLs), a move designed to enhance transparency
The field of oncology is perpetually advancing, with innovative therapies constantly emerging to tackle complex diseases like lung cancer. Ivan Kairatov, a seasoned expert in biopharma with extensive experience in technological innovations and R&D, provides insights into the recent FDA approval of
Amid growing health crises and increasing global competition in pharmaceuticals, a novel FDA initiative aims to fast-track drug reviews by slashing approval times for essential medicines. Can this new approach significantly impact domestic drug manufacturing, or does it introduce unprecedented
